Concord Wealth Partners’s Bionano Genomics BNGO Stock Holding History

Concord Wealth Partners’s Portfolio BNGO Stock Details BNGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.13K	Buy	+1,000	New	+$1.21K	﹤0.01%	768
2026 Q1	–	Sell	-1,000	Closed	-$1.53K	–	269
2025 Q4	$1.53K	Hold	1,000	–	–	﹤0.01%	713
2025 Q3	$1.71K	Buy	+1,000	New	+$3.18K	﹤0.01%	719
2021 Q2	–	Sell	-1	Closed	-$2K	–	1045
2021 Q1	$2K	Buy	+1	New	+$5.64K	﹤0.01%	804

Other funds holding BNGO

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

CAM

Carret Asset Management New York $1.14B AUM 35.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Prudential Financial Newark, New Jersey $91.8B AUM 38.24% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Concord Wealth Partners's BNGO Position: Q2 2026 in Review

Concord Wealth Partners opened a new position in Bionano Genomics (BNGO) in Q2 2026: 1,000 shares worth $1.13K. The stake represents ﹤0.01% of the portfolio and ranks #768 among its holdings. This is a return to the name: Concord Wealth Partners previously reported a position in BNGO as recently as Q4 2025.

Concord Wealth Partners first reported a position in BNGO in Q1 2021 and has held it in 4 quarters since. The position peaked at $2K in Q1 2021. 34 funds tracked by Wall St. Rank hold BNGO as of Q2 2026.

Concord Wealth Partners held 1,000 shares of Bionano Genomics worth $1.13K as of Q2 2026.
Bionano Genomics was a new Concord Wealth Partners position in Q2 2026.
Bionano Genomics made up ﹤0.01% of Concord Wealth Partners's portfolio in Q2 2026, its #768 holding.
Concord Wealth Partners first reported a position in Bionano Genomics in Q1 2021 and has held it in 4 quarters since.
Concord Wealth Partners's Bionano Genomics position peaked at $2K in Q1 2021.
34 funds tracked by Wall St. Rank held Bionano Genomics as of Q2 2026.

Based on Concord Wealth Partners's 13F filing for Q2 2026, filed 27 Jul 2026.